Combinatorial inhibition of epigenetic regulators to treat glioblastoma noah burket , jenna koenig , amanda saratsis indiana university school of medicine; indiana university department of neurosurgery background: glioblastoma multiforme (gbm) is a deadly primary brain cancer that is diagnosed in 12,000 patients in the us annually with a median survival time of 15 months. temozolomide is the standard-of-care for gbm; however, many tumors are resistant, necessitating the expansion of therapeutic options. ezh2 and jmjd3 are two proteins responsible for epigenetic regulation of the genome via histone methylation, with ezh2 also affecting non-histone targets. prior studies showed that inhibition of these proteins decreased cell counts and induced radiosensitivity in gbm. thus, we investigated combined use of ezh2 inhibitor, epz-6438, and jmjd3 inhibitor, gsk-j4, in the treatment of temozolomide-resistant gbm10 cells
who: Burket and Noah J from the Combinatorial Inhibition of Epigenetic Regulators to Treat Glioblastoma Noah Burket1, Jenna Koenig1, Amanda Saratsis, Indiana University School of Medicine have published the article: Combinatorial Inhibition of Epigenetic Regulators to Treat Glioblastoma Noah Burket , Jenna Koenig , Amanda Saratsis Indiana University School of Medicine; Indiana University Department of Neurosurgery Background: Glioblastoma multiforme (GBM) is a deadly primary brain cancer that is diagnosed in 12,000 patients in the US annually with a median survival time of 15 months. Temozolomide is the standard-of-care for GBM; however, many tumors are resistant, necessitating . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.
